The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent

Journal of Virology

Volumn 73, Issue 8, 1999, Pages 6708-6714

  Depolo, Nicholas J ^a   Harkleroad, Cataline E ^a   Bodner, Mordechai ^a   Watt, Andrew T ^a   Anderson, Carol G ^a   Greengard, Judith S ^a   Murthy, Krishna K ^b   Dubensky Jr , Thomas W ^a   Jolly, Douglas J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ARTICLE; CELL CULTURE; CELL LINE; GENE THERAPY; GENE TRANSFER; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SPECIES DIFFERENCE; VIRUS INACTIVATION;

EID: 0032798686     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.8.6708-6714.1999     Document Type: Article

References (48)

1. Barber, J. R., D. J. Jolly, J. G. Respess, and S. M. W. Chang. January 1997. Retroviral packaging cell lines. U.S. patent 5,591,624.
2. Barron, L. G., K. B. Meyer, and F. C. Szoka, Jr. 1998. Effects of complement depletion on the pharmacokinetics and gene delivery mediated by cationic lipid-DNA complexes. Hum. Gene Ther. 9:315-323.
3. Bartholomew, R. M., and A. F. Esser. 1978. Differences in activation of human and guinea pig complement by retroviruses. J. Immunol. 121:1748-1751.
4. Bartholomew, R. M., A. F. Esser, and H. J. Muller Eberhard. 1978. Lysis of oncornaviruses by human serum. Isolation of the viral complement (C1) receptor and identification as p15E. Virology 152:844-853.
5. Cepko, C. 1992. Transduction of genes using retroviral vectors, p. 9.10.1-9.10.7. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology. Greene Publishing Associates, New York, N.Y.
6. Chonn, A., and P. R. Cullis. 1995. Recent advances in liposomal drug-delivery systems. Curr. Opin. Biotechnol. 6:698-708.
7. Cooper, N. R. 1991. Complement evasion strategies of microorganisms. Immunol. Today 12:327-331.
8. Cooper, N. R., F. C. Jensen, R. M. Welsh, Jr., and M. B. Oldstone. 1976. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J. Exp. Med. 144:970-984.
9. Cornelia, K., R. C. Moen, K. Culver, R. A. Morgan, J. R. McLachlin, S. Sturm, J. Selegue, W. London, R. M. Blaese, and W. F. Anderson. 1990. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum. Gene Ther. 1:15-30.
10. Cosset, F. L., Y. Takeuchi, J. L. Battini, R. A. Weiss, and M. K. Collins. 1995. High-liter packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 69:7430-7436.
11. DePolo, N. J. Unpublished data.
12. Galili, U., M. R. Clark, S. B. Shohet, J. Buehler, and B. A. Macher. 1987. Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1 - 3Gal epitope in primates. Proc. Natl. Acad. Sci. USA 84:1369-1373.
13. Galili, U., S. B. Shohet, E. Kobrin, C. L. Stults, and B. A. Macher. 1988. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J. Biol. Chem. 263:17755-17762.
14. Gallagher, R. E., A. W. Schrecker, C. A. Walter, and R. C. Gallo. 1978. Oncornavirus lytic activity in the serum of gibbon apes. J. Natl. Cancer Inst. 60:677-682.
15. Gasmi, M., J. Glynn, M.-J. Jin, D. J. Jolly, J. K. Yee, and S.-T. Chen. 1999. Requirements for efficient production and transduction of HIV-1-based vectors. J. Virol. 73:1828-1834.
16. Greengard, J. S., M. Bodner, J. McCormick, W. R. Edwards, J. L. Sensintaffar, P. L. Sheridan, T. C. Nichols, M. Read, K. M. Brinkhous, D. J. Jolly, and S. M. W. Chang. 1998. In vivo delivery with retroviral vectors: factor VIII gene therapy, abstr. O27, p. 41. In Keystone Symposium: Molecular and Cellular Biology of Gene Therapy.
17. Hamadeh, R. M., G. A. Jarvis, U. Galili, R. E. Mandrell, P. Zhou, and J. M. Grifiss. 1992. Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces. J. Clin. Investig. 89:1223-1235.
18. Irwin, M. J., L. S. Laube, V. Lee, M. Austin, S. Chada, C. G. Anderson, K. Townsend, D. J. Jolly, and J. F. Warner. 1994. Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates. J. Virol. 68:5036-5044.
19. Johnston, J. C., M. Gasmi, L. E. Lim, J. H. Elder, J.-K. Yee, D. J. Jolly, K. P. Campbell, B. L. Davidson, and S. L. Sauter. 1999. Minimal requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J. Virol. 73:4991-5000.
20. Jolly, D. 1994. Viral vector systems for gene therapy. Cancer Gene Ther. 1:51-64.
21. Karavodin, L. M., J. Robbins, K. Chong, D. Hsu, C. Ibanez, S. Mento, D. Jolly, and T. C. Fong. 1998. Generation of a systemic antitumor response with regional intratumoral injections of interferon gamma retroviral vector. Hum. Gene Ther. 9:2231-2241.
22. Kay, M. A., S. Rothenberg, C. N. Landen, D. A. Bellinger, F. Leland, C. Toman, M. Finegold, A. R. Thompson, M. S. Read, and K. M. Brinkhous. 1993. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 262:117-119.
23. Koren, E., M. Kujundzic, M. Koscec, F. A. Neethling, S. V. Richards, Y. Ye, N. Zuhdi, and D. K. Cooper. 1994. Cytotoxic effects of human preformed anti-Gal IgG and complement on cultured pig cells. Transplant. Proc. 26: 1336-1339.
24. Lasic, D. D., and D. Papahadjopoulos. 1995. Liposomes revisited. Science 267:1275-1276.
25. Laube, L. S., M. Burrascano, C. E. Dejesus, B. D. Howard, M. A. Johnson, W. T. Lee, A. E. Lynn, G. Peters, G. S. Ronlov, and K. S. Townsend. 1994. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins. Hum. Gene Ther. 5:853-862.
26. Mahato, R. I., K. Anwer, F. Tagliaferri, C. Meaney, P. Leonard, M. S. Wadhwa, M. Logan, M. French, and A. Rolland. 1998. Biodistribution and gene expression of lipid/plasmid complexes after systemic administration. Hum. Gene Ther. 9:2083-2099.
27. Miller, A. D. 1990. Retrovirus packaging cells. Hum. Gene Ther. 1:5-14.
28. Miller, A. D., and C. Buttimore. 1986. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell Biol. 6:2895-2902.
29. Montefiori, D. C., R. J. Cornell, J. Y. Zhou, J. T. Zhou, V. M. Hirsch, and P. R. Johnson. 1994. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 205:82-92.
30. Morgan, B. P., and S. Meri. 1994. Membrane proteins that protect against complement lysis. Semin. Immunopathol. 15:397-416.
31. Naldini, L., U. Blomer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma, and D. Trono. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
32. Pensiero, M. N., C. A. Wysocki, K. Nader, and G. E. Kikuchi. 1996. Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum. Gene Ther. 7:1095-1101.
33. Rigg, R. J., J. Chen, J. S. Dando, S. P. Forestell, I. Plavec, and E. Bonnlein. 1996. A novel human amphotropic packaging cell line: high liter, complement resistance, and improved safety. Virology 218:290-295.
34. Rother, R. P., W. L. Fodor, J. P. Springhorn, C. W. Birks, E. Setter, M. S. Sandrin, S. P. Squinto, and S. A. Rollins. 1995. A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. J. Exp. Med. 182:1345-1355.
35. Rother, R. P., and S. P. Squinto. 1996. The alpha-galactosyl epitope: a sugar coaling that makes viruses and cells unpalatable. Cell 86:185-188.
36. Russell, D. W., M. S. Berger, and A. D. Miller. 1995. The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines. Hum. Gene Ther. 6:635-641.
37. Saifuddin, M., T. Hedayati, J. P. Atkinson, M. H. Holguin, C. J. Parker, and G. T. Spear. 1997. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J. Gen. Virol. 78:1907-1911.
38. Saifuddin, M., C. J. Parker, M. E. Peeples, M. K. Gorny, S. Zolla-Pazner, M. Ghassemi, I. A. Rooney, J. P. Atkinson, and G. T. Spear. 1995. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J. Exp. Med. 182:501-509.
39. Sallberg, M., J. Hughes, A. Javadian, G. Ronlov, C. Hultgren, K. Townsend, C. G. Anderson, J. O'Dea, J. Alfonso, R. Eason, K. K. Murthy, D. J. Jolly, S. M. Chang, S. J. Mento, D. Milich, and W. T. Lee. 1998. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum. Gene Ther. 9:1719-1729.
40. Schellingerhout, D., A. Bogdanov, Jr., E. Marecos, M. Spear, X. Breakefield, and R. Weissleder. 1998. Mapping the in vivo distribution of herpes simplex virions. Hum. Gene Ther. 9:1543-1549.
41. Sherwin, S. A., R. E. Benveniste, and G. J. Todaro. 1978. Complement-mediated lysis of type-C virus: effect of primate and human sera on various retroviruses. Int. J. Cancer 21:6-11.
42. Smiley, W. R., B. Laubert, B. D. Howard, C. Ibanez, T. C. Fong, W. S. Summers, and F. J. Burrows. 1997. Establishment of parameters for optimal transduction efficiency and antitumor effects with purified high-liter HSV-TK retroviral vector in established solid tumors. Hum. Gene Ther. 8:965-977.
43. Takeuchi, Y., S.-H. Liong, P. D. Bieniasz, U. Jäger, C. D. Porter, T. Friedmann, M. O. McClure, and R. A. Weiss. 1997. Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(α1-3)galactosylation. J. Virol. 71:6174-6178.
44. Takeuchi, Y., C. D. Porter, K. M. Strahan, A. F. Preece, K. Gustafsson, F. L. Cosset, R. A. Weiss, and M. K. Collins. 1996. Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature 379:85-88.
45. Takeuchi, Y., F.-L. C. Cosset, P. J. Lachmann, H. Okada, R. A. Weiss, and M. K. L. Collins. 1994. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J. Virol. 68:8001-8007.
46. Welsh, R. M., C. L. O'Donnell, D. J. Reed, and R. P. Rother. 1998. Evaluation of the Galα1-3Gal epitope as a host modification factor eliciting natural 7umoral immunity to enveloped viruses. J. Virol. 72:4650-4656.
47. Welsh, R. M., Jr., N. R. Cooper, F. C. Jensen, and M. B. Oldstone. 1975. Human serum lyses RNA tumour viruses. Nature 257:612-614.
48. Welsh, R. M., Jr., F. C. Jensen, N. R. Cooper, and M. B. Oldstone. 1974. Inactivation of lysis of oncornaviruses by human serum. Virology 74:432-440.